Development of new oral cancer treatments focused on mTOR inhibition leading to the anti-aging prevention and the healthy life-span extension

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K11292
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Yamaguchi University
• Principal Investigator: HARADA Koji 山口大学, 大学院医学系研究科, 助教 (60253217)
• Research Collaborator: FERDOUS Tarannum ; MINAMI Haruyasu ; FUJIWARA Rieko
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: mTOR阻害剤 / ラパマイシン / ５-FU / 老化防止 / 健康寿命延長 / 口腔癌

Outline of Final Research Achievements

We investigated the combined effect one of mTOR inhibitors (rapamycin, everolimus or temsirolimus) and any of conventional anticancer agents (5-FU, CDDP, DOC, PTX, C-mab or radiation). Rapamycin in combination with 5-FU exerted maximum growth inhibitory effects on OSCC cell lines and nude mice tumors. Immunohistochemical staining showed that the expressions of p16, VEGF and podoplanin were down-regulated, and the expressions of PI3K, Akt , p27, and p21 were up-regulated on nude mice tumors treated with rapamycin and 5-FU.
These findings suggested that the combined therapy of rapamycin and 5-FU might be an new oral cancer treatments focused on mTOR inhibition leading to the anti-aging prevention and the healthy life-span extension.

Free Research Field

口腔外科学